闫晓杰, 夏学明, 刘钦兰, 白莉. 139例晚期食管鳞状细胞癌的一线化疗及生存分析[J]. 解放军医学院学报, 2015, 36(7): 671-674,719. DOI: 10.3969/j.issn.2095-5227.2015.07.009
引用本文: 闫晓杰, 夏学明, 刘钦兰, 白莉. 139例晚期食管鳞状细胞癌的一线化疗及生存分析[J]. 解放军医学院学报, 2015, 36(7): 671-674,719. DOI: 10.3969/j.issn.2095-5227.2015.07.009
YAN Xiaojie, XIA Xueming, LIU Qinlan, BAI Li. First-line chemotherapy of patients with advanced esophageal squamous cell carcinoma: A survival analysis of 139 cases[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2015, 36(7): 671-674,719. DOI: 10.3969/j.issn.2095-5227.2015.07.009
Citation: YAN Xiaojie, XIA Xueming, LIU Qinlan, BAI Li. First-line chemotherapy of patients with advanced esophageal squamous cell carcinoma: A survival analysis of 139 cases[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2015, 36(7): 671-674,719. DOI: 10.3969/j.issn.2095-5227.2015.07.009

139例晚期食管鳞状细胞癌的一线化疗及生存分析

First-line chemotherapy of patients with advanced esophageal squamous cell carcinoma: A survival analysis of 139 cases

  • 摘要: 目的 研究晚期食管鳞状细胞癌(esophageal squamous cell carcinoma,ESCC)一线化疗情况及影响预后的相关因素。 方法 回顾性分析2009年1月-2014年8月在我院初治Ⅳ期行一线化疗的139例ESCC患者的临床资料,其中男性124例,女性15例,年龄39 ~ 78岁,中位年龄为58岁。采用Kaplan-Meier法分析总生存时间(overall survival,OS),单因素和Cox回归多因素分析影响生存及预后的相关因素。 结果 139例患者化疗总有效率为46.8%,1年、3年、5年生存率分别为55.4%、15.8%、4.5%。一线化疗的中位OS为13.9个月,单因素及多因素分析显示,肝转移(P=0.028)、一线化疗疗效(P=0.001)、是否胸部放疗(P=0.000)与OS有关。 结论 有无肝转移、化疗是否有效、是否接受放疗对患者预后有重要影响,无肝转移患者的预后好,化疗评价有效、接受放疗有益于生存。

     

    Abstract: Objective To study the survival of patients with advanced esophageal squamous cell carcinoma (ESCC) in first-line chemotherapy and the factors related to the prognosis. Methods Clinical data about 139 advanced ESCC patients with 124 males and 15 females who received first-line chemotherapy in our hospital from January 2009 to August 2014 were retrospectively analyzed. The distribution of age range was 39 to 78 years old with median age of 58 years old. Kaplan-Meier method was used to calculate the overall survival (OS). Univariate analysis and Cox regression analysis were used to detect the influence factors of survival and prognosis. Results The response rate of 139 patients with chemotherapy was 46.8% with 1-year, 3-year, 5-year survival rates of 55.4%, 15.8%, 4.5%, respectively. The median OS of patients with advanced ESCC in first-line chemotherapy was 13.9 months. According to the results of univariate and COX multivariate analysis, OS of patients with advanced ESCC was closely associated with liver metastasis (P=0.028), curative effect of first-line chemotherapy (P=0.001) and thoracic radiotherapy (P=0.000). Conclusion Liver metastasis, curative effect of first-line chemotherapy and thoracic radiotherapy have important influences on the prognosis of patients with ESCC. The patients who are absence of liver metastasis have better prognosis. It is beneficial to survival if patients have effective curative effect of first-line chemotherapy and receive thoracic radiotherapy.

     

/

返回文章
返回